Eli Lilly and Company (NYSE:LLY) Shares Down 2.3% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) fell 2.3% on Monday . The stock traded as low as $1,071.60 and last traded at $1,079.9610. 2,648,538 shares were traded during mid-day trading, a decline of 17% from the average session volume of 3,202,486 shares. The stock had previously closed at $1,105.00.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s obesity franchise got a major boost as CVS Caremark and the other two largest U.S. PBMs now cover its full obesity portfolio, including Zepbound and the newly approved oral drug Foundayo, widening access and improving the growth outlook. Article Title
• Positive Sentiment: The company is signaling a bigger M&A push, with its top dealmaker saying Lilly may use GLP-1 profits to fund acquisitions in new therapeutic areas, which could diversify the pipeline and reduce dependence on obesity drugs. Article Title
• Positive Sentiment: Lilly continues to deepen its pipeline through licensing and acquisition activity, including deals tied to next-gen vaccines, intestinal disease treatment, and cardiometabolic drugs, reinforcing long-term growth expectations. Article Title
• Positive Sentiment: Recent clinical updates were also favorable, including positive Retevmo data in lung cancer and expanded attention on Lilly’s hematology portfolio ahead of the EHA meeting, supporting confidence in the non-obesity pipeline. Article Title
• Neutral Sentiment: Lilly also issued a tougher stance toward 340B hospitals, demanding claims data or risking lost discounts; this could pressure provider relationships even though it may help pricing discipline. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Argus upped their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Berenberg Bank increased their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. CICC Research boosted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Finally, Rothschild & Co Redburn upped their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s 50-day moving average price is $959.18 and its 200-day moving average price is $1,010.74. The company has a market cap of $1.00 trillion, a P/E ratio of 37.82, a PEG ratio of 1.18 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the firm earned $3.34 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Cidel Asset Management Inc. increased its position in Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after buying an additional 5,591 shares in the last quarter. Spire Wealth Management boosted its holdings in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after acquiring an additional 592 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares during the period. Farther Finance Advisors LLC grew its stake in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in shares of Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after acquiring an additional 5,595 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.